Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taro Pharmaceuticals

This article was originally published in The Tan Sheet

Executive Summary

Will market "several" topical dermatological and vaginal OTC products under an agreement with Schering-Plough that results from a previously announced joint research effort, Hawthorne, N.Y.-based Taro announces March 12. The two firms announced a joint R&D agreement on certain topicals in April 1998 ("The Tan Sheet" April 27, 1998, In Brief). Distribution of the products is expected to begin in the first half with additional products slated for introduction in the first quarter 2000. Taro will distribute the products under its own label and under various private label customers' OTC labels, the firm notes. Taro already markets topical 1% clotrimazole for athlete's foot and jock itch, which is comparable to Schering's Lotrimin AF. Clotrimazole also is the active ingredient in Schering vaginal yeast infection treatment Gyne-Lotrimin

You may also be interested in...



Private Label Three-Day Yeast Infection Cream Offered By Taro

Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.

Private Label Three-Day Yeast Infection Cream Offered By Taro

Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.

Private Label Three-Day Yeast Infection Cream Offered By Taro

Taro Pharmaceutical Industries' new drug application for clotrimazole 2% three-day cream was approved April 14 as a private label OTC vaginal yeast infection treatment identical to Schering-Plough's Gyne-Lotrimin 3 Cream. The product will appear on store shelves of major chains and mass merchandisers beginning in May.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel